Among all patients, the median progression‑free survival (mPFS) time was 14.5 months. The objective response rate was 56.52% and the disease control rate was 78.26%. A total of 23 patients received oral treatment with crizotinib, of which 13 (56.52%), 5 (21.74%) and 5 (21.74%) patients demonstrated a partial response, stable disease and progressive disease, respectively. Statistically significant differences were identified for sex, TNM staging and EGFR gene status between ROS1 fusion gene‑positive and ‑negative patients (P<0.001). The epidermal growth factor receptor (EGFR) gene status included 60 cases of wild‑type, 1 case of co‑mutation and 6 unknown cases. According to Tumor‑Node‑Metastasis (TNM) staging, 4 cases were stage I‑IIIa and 63 (94.02%) were stage IIIb‑IV. Among these cases, 59 (88.06%) were adenocarcinoma and 8 were non‑adenocarcinoma. The ROS1 fusion was identified in 67 out of 2,617 cases (2.56%), including 21 cases that were male and 46 cases that were female. ROS1 fusion genes were detected by reverse transcription‑quantitative polymerase chain reaction, fluorescence in situ hybridization or next‑generation sequencing techniques, and patients positive for the ROS1 fusion gene received oral treatment with crizotinib. A retrospective analysis of 2,617 cases of NSCLC diagnosed between January 2013 and December 2016 was performed. The present study explored the clinicopathological features and clinical efficacy of crizotinib in patients with ROS1‑positive NSCLC.
C‑ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement forms a novel molecular subgroup of non‑small cell lung cancer (NSCLC).
0 kommentar(er)
